- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03214159
Bioequivalence Study (Preliminary Study) of Ritonavir Versus NORVIR in Healthy Chinese Subjects
An Open-label, Randomized Bioequivalence Study (Preliminary Study) of Ritonavir Versus NORVIR in Healthy Chinese Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- First Affiliated Hospital of Zhejiang University
-
Hanzhou, Zhejiang, China, 310003
- First Affiliated Hospital of Zhejiang University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult volunteers of 18-45 years old.
- Male (weight ≥50kg)
- Body mass index (BMI) between 19~28 kg/m2;
- In good health as determined by a physician/investigator based on medical history, vital signs, electrocardiogram (ECG), laboratory tests and physical examination findings at screening;
- Male participant agrees to use adequate contraception and have no plan to donate sperm from signing of informed consent form throughout the duration of the study and for 6 months after the last dose of study drug;
- Subject who totally understand the aim and progress of this clinical trial, make decision by his/her free will, and signed a consent form to follow the progress;
- In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
Exclusion Criteria:
- Subject who cannot tolerate venipuncture.
- Allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator;
- Subject who has past or present history of any serious diseases, including (but not limited to) digestive, cardiovascular, respiratory, urinary, musculoskeletal, endocrine, psychiatric or neurological, hematologic, immunological or metabolic disorders;
- Abnormal results of physical examination (hematology, urine test,blood biochemistry etc.), vital signs, laboratory profile, a 12-lead electrocardiogram (ECG) or x-ray with clinical significance.
- A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test;
- Subject who refuse to use adequate contraception from signing of informed consent form throughout the duration of the study and for 6 months after the last dose of study drug;
- Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as alcohol consumption exceeding 14 units per week) within 6 months preceding this study or is unwilling to agree to abstain from alcohol and drugs throughout the study;
- Heavy smokers (>5 cigarettes per day) within 6 months preceding this study or is unwilling to agree to abstain from smoking throughout the study;
- Positive test results for alcohol or drug at Screening;
- History of hospitalization or surgery within 3 months preceding this study.
- Blood donation within the last 2 months (>= 400 ml), or have a plan to donate blood within 1 month after this study;
- Intake of any other drug which might influence the results of the trial during two weeks previous to the start of the study.
- Participation in another study with an investigational drug within the last 3 months preceding this study;
- History of gastrointestinal surgery, vagotomy, enterotomy or other surgery that may influence gastrointestinal motility,PH or gastrointestinal absorption.
- Intake of grapefruit or orange (or other food containing grapefruit or orange) 3 days previous to the start of the study. Intake of tea,coffee or other drink containing coffee more than 1L per day.
- Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive Ritonavir.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: group 1
During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition. Intervention: cylcle 1 Drug: Ritonavir tablet 100mg cylcle 2 Drug: NORVIR tablet 100mg cylcle 3 Drug: Ritonavir tablet 100mg cylcle 4 Drug: NORVIR tablet 100mg |
Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
NORVIR Tablet is a generic product manufactured by AbbVie.
NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
|
Experimental: group 2
During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition. Intervention: cylcle 1 Drug: NORVIR tablet 100mg cylcle 2 Drug: Ritonavir tablet 100mg cylcle 3 Drug: NORVIR tablet 100mg cylcle 4 Drug: Ritonavir tablet 100mg |
Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
NORVIR Tablet is a generic product manufactured by AbbVie.
NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax: Maximum Observed Plasma Concentration for ritonavir
Time Frame: 36 hours post-dose on Day 1,7,13 and 19
|
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
|
36 hours post-dose on Day 1,7,13 and 19
|
Tmax
Time Frame: 36 hours post-dose on Day 1,7,13 and 19
|
Time to Reach the Maximum Plasma Concentration
|
36 hours post-dose on Day 1,7,13 and 19
|
AUC(0-inf): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for ritonavir
Time Frame: Time Frame: 36 hours post-dose on Day 1,7,13 and 19
|
AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity
|
Time Frame: 36 hours post-dose on Day 1,7,13 and 19
|
AUC(0-36h): Area Under the Plasma Concentration-Time Curve From Time 0 to 36 hours Postdose for ritonavir
Time Frame: 36 hours post-dose on Day 1,7,13 and 19
|
AUC(0-36h) is measure of area under the plasma concentration and time curve from Time 0 to 36 hours postdose.
|
36 hours post-dose on Day 1,7,13 and 19
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZYYY-LTNW-BE-2017-05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
National Heart, Lung, and Blood Institute (NHLBI)TerminatedHealthy | Healthy Volunteer | HVUnited States
-
BiogenRecruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
Angion Biomedica CorpQuotient SciencesNot yet recruitingHealthy VolunteerUnited States
-
University Hospital, ToursRecruitingNeurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults (PROSCEA)Healthy VolunteerFrance
-
BiogenActive, not recruiting
-
TeneoFour Inc.Novotech (Australia) Pty LimitedCompletedHealthy VolunteerAustralia
-
Spero TherapeuticsCompleted
Clinical Trials on Ritonavir Tablet 100mg
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Completed
-
GlaxoSmithKlineCompleted
-
Xijing Hospital of Digestive DiseasesCompletedColorectal AdenomasChina
-
Shanghai Jiatan Pharmatech Co., LtdCompleted
-
SensorionCompletedAcute Unilateral Vestibulopathy (AUV)United States, Israel, France, Korea, Republic of, Hungary, Germany, Czechia, Italy
-
GlaxoSmithKlineTerminatedHIV-1Australia, Belgium, Canada, France, Germany, Greece, Italy, Spain, United Kingdom
-
GlaxoSmithKlineTerminated
-
CSPC Ouyi Pharmaceutical Co., Ltd.CompletedHealthy ParticipantsChina
-
GlaxoSmithKlineCompletedBone Marrow TransplantationUnited States
-
Bright Future Pharmaceuticals Factory O/B Bright...Chinese University of Hong KongUnknown